See the Future Clearly
Let's Assess AMD Risk Years Before Vision Loss
De-Risked Revenue Strategy | Q1 2027 CLIA Launch
* Proof-of-concept study accuracy. Performance characteristics to be validated in clinical studies. This test has not been cleared or approved by the US Food and Drug Administration.
Our proactive approach combines standard medical care with cutting-edge AI analysis to help identify risks years before symptoms appear.
Patients visit their family doctor for a routine check-up and initial consultation.
Blood is withdrawn at the clinic and securely transported to our specialist lab.
Our AI-powered Risk Assessment Platform analyzes biomarkers in the sample.
Comprehensive results enable proactive discussions between doctor and patient.
Founder & CEO
Co-Founder
Healthcare is shifting from reactive to predictive. We are positioned at the convergence of three massive market shifts.
No blood-based AMD risk assessment exists today. We aren't just entering the market; we are building the category and setting the clinical benchmark.
The March 2025 court ruling vacated the FDA's LDT Final Rule. "This enables CLIA-certified Laboratory Developed Tests (LDTs) and enables faster commercialization than the years-long FDA process."
Novartis's AMD prevention therapy completes Phase 2 trials in October 2026. Big Pharma would require risk assessment platforms to identify high-risk patients before symptoms appear
Transparent progress toward commercialization
Whether you're a patient, healthcare provider, or investor, we have resources tailored for you.